Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Equity Ratio: 2011-2025

Historic Equity Ratio for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to 0.72.

  • Niagen Bioscience's Equity Ratio rose 18.44% to 0.72 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.72, marking a year-over-year increase of 18.44%. This contributed to the annual value of 0.68 for FY2024, which is 30.40% up from last year.
  • Latest data reveals that Niagen Bioscience reported Equity Ratio of 0.72 as of Q3 2025, which was up 2.68% from 0.70 recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Equity Ratio ranged from a high of 0.72 in Q3 2025 and a low of 0.45 during Q2 2022.
  • Moreover, its 3-year median value for Equity Ratio was 0.57 (2024), whereas its average is 0.60.
  • Its Equity Ratio has fluctuated over the past 5 years, first slumped by 30.36% in 2022, then skyrocketed by 30.40% in 2024.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Equity Ratio stood at 0.55 in 2021, then fell by 3.30% to 0.53 in 2022, then dropped by 2.39% to 0.52 in 2023, then spiked by 30.40% to 0.68 in 2024, then climbed by 18.44% to 0.72 in 2025.
  • Its last three reported values are 0.72 in Q3 2025, 0.70 for Q2 2025, and 0.68 during Q1 2025.